Search for Genetic Factors Predictive of Response to Chemotherapy in Patients With or Who Has a Mammary Adenocarcinoma in Neo-adjuvant or Metastatic Setting

Centre Oscar Lambret1 site in 1 country900 target enrollmentNovember 28, 2007

ConditionsBreast Cancer

Overview

Phase: Not Applicable
Intervention: Not specified
Conditions: Breast Cancer
Sponsor: Centre Oscar Lambret
Enrollment: 900
Locations: 1
Primary Endpoint: Histologic complete response (Chevallier and Sataloff) or tumor response (RECIST)
Status: Completed
Last Updated: last month

Overview Investigators Eligibility Criteria Outcomes Sites Similar Trials

Overview

Brief Summary

RATIONALE: Studying the genes expressed in samples of blood from patients with cancer may help doctors identify biomarkers related to cancer. It may also help doctors predict how patients will respond to chemotherapy.

PURPOSE: This clinical trial is studying blood samples in patients with breast cancer.

Detailed Description

OBJECTIVES: * Identify constitutional gene variants associated with a change in response. OUTLINE: Blood samples are collected periodically for analysis of genetic factors.

Registry

clinicaltrials.gov

Start Date

November 28, 2007

End Date

January 6, 2012

Last Updated

last month

Study Type

Observational

Sex

Female

Investigators

Sponsor

Centre Oscar Lambret

Responsible Party

Sponsor

Eligibility Criteria

Inclusion Criteria

•DISEASE CHARACTERISTICS:
•Histologically confirmed breast carcinoma
•Received first-line chemotherapy (in neoadjuvant or metastatic setting) comprising anthracyclines and/or taxanes, including for a second primary cancer
•Patient agrees to conservative surgery
•Hormone receptor status not specified
•PATIENT CHARACTERISTICS:
•Menopausal status not specified
•No contraindication for chemotherapy comprising anthracyclines and/or taxanes
•PRIOR CONCURRENT THERAPY:
•See Disease Characteristics